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Introduction {#sec001}
============

Levodopa improves motor symptoms in patients with Parkinson's disease (PD). However, many patients treated with levodopa chronically encounter levodopa-induced dyskinesia (LID). LID develops in approximately 60% of patients within at 5 years of levodopa therapy \[[@pone.0237472.ref001]--[@pone.0237472.ref003]\], and it eventually affects most of patients treated with levodopa \[[@pone.0237472.ref001], [@pone.0237472.ref004], [@pone.0237472.ref005]\].

Previous studies have determined risk factors for LID to be younger age at PD onset \[[@pone.0237472.ref001], [@pone.0237472.ref004], [@pone.0237472.ref006], [@pone.0237472.ref007]\], female sex \[[@pone.0237472.ref007]\], lower body weight \[[@pone.0237472.ref007]\], higher levodopa dose \[[@pone.0237472.ref001], [@pone.0237472.ref004], [@pone.0237472.ref006], [@pone.0237472.ref007]\], and more severe motor symptoms at baseline \[[@pone.0237472.ref007]--[@pone.0237472.ref009]\], lower dopamine transporter availability at baseline \[[@pone.0237472.ref006], [@pone.0237472.ref009]\], and higher dopamine turnover rate in the posterior putamen at baseline \[[@pone.0237472.ref010]\]. Among these risk factors, high levodopa dose is one of the most commonly reported; however, there was no established method for assessing levodopa dose which is usually increased during long-term therapy. In previous studies, levodopa dose has been defined as the initial dose \[[@pone.0237472.ref001], [@pone.0237472.ref004]\], cumulative dose \[[@pone.0237472.ref008]\], or dose at LID onset/last dose in LID-free patients \[[@pone.0237472.ref006], [@pone.0237472.ref007]\]. However, the levodopa dose usually increases with disease progression in general practice and clinical trials \[[@pone.0237472.ref003], [@pone.0237472.ref011]\], and the rate of dose increase varies among patients.

Results from clinical trials consistently showed that parkinsonian motor symptoms improved within 6 to 9 months from the initiation of medication and then progressed again with a constant rate \[[@pone.0237472.ref002], [@pone.0237472.ref003], [@pone.0237472.ref012], [@pone.0237472.ref013]\]. Similar to clinical trials, observational studies have also shown that the initial drug dose is titrated within 6 to 12 months from the initiation of medication \[[@pone.0237472.ref001], [@pone.0237472.ref004], [@pone.0237472.ref014]\], and the rate of subsequent dose increases is similar for many years \[[@pone.0237472.ref014]\]. Therefore, assessing levodopa dose using initial titration dose and rate of dose increase can help analyzing the longitudinal effect of levodopa dose on development of LID.

In this study, we collected longitudinal data on levodopa dose from patients with PD who experienced LID during medical therapy, and we explored the relationship between levodopa dose and time to development of LID.

Materials and methods {#sec002}
=====================

Subjects {#sec003}
--------

We reviewed medical records from 4 referral hospitals in South Korea (Wonju Severance Christian Hospital, Bundang Jesaeng General Hospital, Severance Hospital, Dongtan Sacred Heart Hospital, and Severance Hospital) between March 2007 and October 2018 and selected data of PD patients who experienced LID. PD was diagnosed according to the clinical criteria of UK PD brain bank \[[@pone.0237472.ref015]\], and patients who showed atypical features listed in step 2 of the criteria during treatment period were excluded from the study. Patients who had been treated with dopaminergic drugs or dopamine receptor blocking agents before visiting our hospitals were also excluded. Among them, we selected patients who initiated medical treatment with levodopa. Patients who took dopamine agonist or monoamine oxidase B (MAO-B) inhibitor prior to levodopa initiation, a dopamine-receptor blocking agent during treatment period, or amantadine before development of LID were also excluded. Patients with impulse control disorders, psychosis, or dementia were not included because these conditions may affect drug dose.

LID was assessed based on medical record. For regular management for PD, patients usually have been visiting outpatient clinic of 5 experts in movement disorders (J.Y.H., M.K.S., S.Y.K., Y.H.S., and P.H.L.) every 2--3 months. When patient reported symptom suggesting LID or dyskinetic movement was observed in the clinic, clinicians recorded the information for LID. The onset of LID was defined as 1) the first day that LID was observed by clinician when patient did not perceive their dyskinesia, 2) the day indicated by patient when LID was observed by clinician and the patient remembered the day that LID had begun. Patients who skipped visit more than 6 months were excluded from the study. Because short latency to onset of LID may make rate of dose increase overestimated, patients who LID developed within 2 years from levodopa initiation were excluded.

Subjects were grouped according to time to development of LID from initiation of levodopa: E (Early, 2 years \< time to LID onset ≤ 4 years), M (Middle, 4 years \< time to LID onset ≤ 6 years), L (Late, 6 years \< time to LID onset).

Motor symptoms were assessed using Unified PD Rating Scale (UPDRS) motor score (part III) and modified Hoehn and Yahr stage, and the scores rated at *de novo* status were used in this study.

Ethics statement {#sec004}
----------------

The study protocol was approved by the Institutional Review Board (IRB) of the Wonju Severance Christian Hospital (approval number: 2018-10-0007), and the study was conducted according to the Declaration of Helsinki. The requirement for written informed consent was exempted by the IRB and local regulation due to the retrospective design.

Drug dose {#sec005}
---------

Patients took equal dose of levodopa three times a day, and the treatment was usually initiated with 50mg of levodopa three times a day. When dose increase was needed, the single dose was usually increased by 50mg (150mg a day). Data for the dose of antiparkinsonian drugs at 6 months, 1 year, and every year after that from initiation of levodopa were collected from prescription records. The levodopa-equivalent dose (LED) was calculated according to a published formulation \[[@pone.0237472.ref016]\].

To reflect change of drug dose over disease progression, the drug dose was assessed as initial titration dose and rate of dose increase. Initial titration dose was defined as the daily dose of levodopa at 6 months from the initiation of medication \[[@pone.0237472.ref014]\], and the rate of dose increase was calculated as following: {(drug dose at onset of LID)--(drug dose at 6 months \[initial titration dose\])} / {(years at onset of LID)--(0.5 year)}. Initial titration dose and rate of dose increase for LED were calculated with same method.

Statistical analyses {#sec006}
--------------------

Analysis of variance (ANOVA) and chi-square test were used to compare groups, and *post hoc* analyses were conducted with Bonferroni's method. Factors associated with time to LID onset were explored using Pearson's correlation and multivariable linear regression models with stepwise selection method. Because data for UPDRS motor score of 61 patients were missed, linear regression analyses were conducted with data from 89 patients. Statistical analyses were performed with SPSS Statistics 23 (IBM SPSS, Armonk, NY, USA), and *p*\<0.05 was considered significant. Graphic illustrations were obtained using GraphPad Prism version 7.02 for Windows (GraphPad Software, La Jolla, CA, USA).

Results {#sec007}
=======

Demographic and clinical characteristics {#sec008}
----------------------------------------

According to the inclusion and exclusion criteria of this study, a total of 150 patients were collected for this study (58 for E, 51 for M, and 41 for L group). Demographic and clinical characteristics of study subjects are presented in [Table 1](#pone.0237472.t001){ref-type="table"}. Sex, age at PD onset, age at initiation of levodopa therapy, and time between PD onset and initiation of levodopa therapy did not differ significantly among groups. UPDRS motor score at levodopa initiation were higher in E (29.2 vs. 22.1, *post hoc p* = 0.029) than L group, however modified Hoehn and Yahr stage was not different among groups.

10.1371/journal.pone.0237472.t001

###### Demographic and clinical characteristics of subjects and drug dose.

![](pone.0237472.t001){#pone.0237472.t001g}

                                                                       Total (n = 150)   E (n = 58)      M (n = 51)      L (n = 41)      p-value   Intergroup comparison
  -------------------------------------------------------------------- ----------------- --------------- --------------- --------------- --------- -----------------------
  Female, n (%)                                                        94 (62.7)         40 (69.0)       29 (56.9)       25 (61.0)       0.413     
  Age at PD onset, year                                                63.9 ± 8.7        62.9 ± 8.9      64.0 ± 8.4      65.1 ± 8.6      0.469     
  Age at levodopa initiation, year                                     65.3 ± 8.4        64.4 ± 8.6      65.4 ± 8.2      66.5 ± 8.6      0.470     
  PD onset to levodopa initiation, year                                1.4 ± 1.2         1.5 ± 1.2       1.4 ± 1.1       1.4 ± 1.4       0.842     
  UPDRS motor score [^a^](#t001fn002){ref-type="table-fn"}             27.2 ± 10.0       29.2 ± 8.5      27.7 ± 11.9     22.1 ± 8.5      0.033     E\>L
  Modified Hoehn & Yahr stage [^b^](#t001fn003){ref-type="table-fn"}   2.2 ± 0.5         2.2 ± 0.5       2.1 ± 0.5       2.0 ± 0.3       0.283     
  Levodopa dose                                                                                                                                    
  Initial titration dose (at 6 months)                                 383.3 ± 140.9     406.9 ± 161.1   382.6 ± 133.2   350.6 ± 113.5   0.147     
  Rate of increase, mg/day/year                                        54.1 ± 55.5       69.9 ± 70.6     46.1 ± 45.7     41.5 ± 33.9     0.019     E\>L
  Dose at LID onset, mg/day                                            596.7 ± 220.6     578.0 ± 226.0   583.8 ± 190.1   639.0 ± 246.5   0.353     
  Levodopa-equivalent dose                                                                                                                         
  Initial titration dose (at 6 months)                                 505.5 ± 154.7     518.6 ± 168.9   517.8 ± 148.4   460.9 ± 135.9   0.129     
  Rate of increase, mg/day/year                                        87.1 ± 74.2       113.8 ± 91.6    75.8 ± 63.5     63.3 ± 41.2     0.001     E\>M, E\>L
  Dose at LID onset, mg/day                                            841.3 ± 258.4     797.6 ± 262.1   848.3 ± 253.4   894.4 ± 254.7   0.181     
  Drug use at LID onset, n (%)                                                                                                                     
  Dopamine agonists                                                    119 (79.3)        41 (70.7)       45 (88.2)       33 (80.5)       0.076     
  MAO-B inhibitors                                                     44 (29.3)         14 (24.1)       17 (33.3)       13 (31.7)       0.532     
  Entacapone                                                           60 (40.0)         20 (34.5)       19 (37.3)       21 (51.2)       0.218     
  Anticholinergics                                                     19 (12.7)         8 (13.8)        7 (13.7)        4 (9.8)         0.806     

PD, Parkinson's disease; UPDRS, Unified PD rating scale; LID, levodopa-induced dyskinesia; MAO-B, monoamine oxidase B.

^a^ Data of 89 patients (41 for E, 29 for M, and 19 for L group) existed.

^b^ Data of 92 patients (42 for E, 29 for M, and 21 for L group) existed.

Drug dose {#sec009}
---------

The mean levodopa dose and LED over time according to the groups are shown in [Fig 1](#pone.0237472.g001){ref-type="fig"}, and data for initial titration dose and rate of dose increase are presented in [Table 1](#pone.0237472.t001){ref-type="table"}. Initial titration dose of levodopa and LED were similar among groups. The rate of levodopa increase was higher in E group than L group (69.9 vs. 41.5 mg/day/year, *post hoc p* = 0.034), and rate of LED increase was higher in E group than both M (113.8 vs. 75.8 mg/day/year, *post hoc p* = 0.019) and L groups (113.8 vs. 63.3 mg/day/year, *post hoc p* = 0.002). Both levodopa dose and LED at onset of LID were not significantly different among groups. The frequency of use of other antiparkinsonian drugs other than levodopa at onset of LID did not differ among groups.

![Levodopa and levodopa equivalent dose.\
Levodopa (a) and levodopa equivalent dose (b) of each subjects. Left and right ends of each light line indicate initial titration dose and dose at onset of LID of each subject, respectively. The mean doses of subject groups are expressed as heavy lines.](pone.0237472.g001){#pone.0237472.g001}

Risk factor for early LID {#sec010}
-------------------------

Pearson's correlation analysis ([Fig 2](#pone.0237472.g002){ref-type="fig"}) revealed that time to onset of LID was correlated with initial titration dose of levodopa (r = -0.17, p = 0.043), rate of dose increase for levodopa (r = -0.21, p = 0.009) and LED (r = -0.29, p\<0.001), UPDRS motor score (r = -0.31, p = 0.003), and modified Hoehn and Yahr stage (r = -0.22, p = 0.033). Initial titration dose of LED tended to correlate with time to onset of LID (r = -0.15, p = 0.066). However, time to onset of LID was not associated with age at onset of PD, age at levodopa initiation, time between PD onset and initiation of levodopa therapy, sex difference, and use of dopamine agonist, MAO-B inhibitor, entacapone, or anticholinergics.

![Time to onset of levodopa-induced dyskinesia and drug dose.\
Correlation between time to onset of levodopa-induced dyskinesia (LID) and initial titrating levodopa dose (a), time to LID and initial titrating levodopa-equivalent dose (b), time to LID and rate of increase in levodopa dose (c), and time to LID and rate of increase in levodopa-equivalent dose (d).](pone.0237472.g002){#pone.0237472.g002}

Multivariable linear regression models for levodopa dose (F = 7.204, p\<0.001, R^2^ = 0.203) exhibits that female sex (β = -0.846, p = 0.028), higher rate of levodopa increase (β = -0.010, p = 0.004), and higher UPDRS motor score at baseline (β = -0.054, p = 0.003) were associated with early onset of LID ([Table 2](#pone.0237472.t002){ref-type="table"}). Linear regression model for LED (F = 9.716, p\<0.001, R^2^ = 0.255) also found that female sex (β = -0.831, p = 0.024), higher rate of LED increase (β = -0.009, p\<0.001), higher UPDRS motor score at baseline (β = -0.053, p = 0.003) were associated with early onset of LID.

10.1371/journal.pone.0237472.t002

###### Results of multiple linear regression analyses to predict time to levodopa-induced dyskinesia.

![](pone.0237472.t002){#pone.0237472.t002g}

                                             Levodopa [^a^](#t002fn002){ref-type="table-fn"}   Levodopa-equivalent dose [^b^](#t002fn003){ref-type="table-fn"}                                     
  ------------------------------------------ ------------------------------------------------- ----------------------------------------------------------------- ------- -------- ---------------- ---------
  Female                                     -0.846                                            -1.599, -0.093                                                    0.028   -0.831   -1.552, -0.111   0.024
  Rate of dose increase                      -0.010                                            -0.017, -0.003                                                    0.004   -0.009   -0.014, -0.005   \<0.001
  UPDRS motor score at levodopa initiation   -0.054                                            -0.090, -0.019                                                    0.003   -0.053   -0.087, -0.018   0.003

CI, confidential interval; UPDRS, Unified Parkinson's Disease Rating Scale.

^a^ *F* = 7.204, p\<0.001, R^2^ = 0.203.

^b^ *F* = 9.716, p\<0.001, R^2^ = 0.255.

Discussion {#sec011}
==========

The present study was conducted with a relatively large number of patients with LID and explored the effect of longitudinal changes in levodopa dose or LED on time to onset of LID. The results demonstrated that higher rate of dose increase of dopaminergic drugs were significantly associated with the early onset of LID.

Patients who developed LID early had more severe motor symptoms at initiation of levodopa therapy than did patients with late onset of LID, as in previous studies \[[@pone.0237472.ref007]--[@pone.0237472.ref009]\]. Functional neuroimaging studies also demonstrated that lower dopaminergic activity in de novo patients predicts early LID onset \[[@pone.0237472.ref006], [@pone.0237472.ref009], [@pone.0237472.ref010], [@pone.0237472.ref017]\]. The association between early onset of LID and higher initial levodopa dose was also observed in previous studies. The mean levodopa dose over the first 6 months \[[@pone.0237472.ref001]\] and maintenance dose of levodopa within the first year \[[@pone.0237472.ref004]\] were predictors of early onset of LID. Given that motor symptoms and initial dose of dopaminergic drug may reflect the severity of motor symptoms at diagnosis, these findings agree with previous reports suggesting that more severe dopaminergic denervation when beginning treatment is a risk factor for LID \[[@pone.0237472.ref001], [@pone.0237472.ref004]\]. In the present study, initial titration dose of levodopa or LED showed significant negative correlation with time to onset of LID, however the final regression models included UPDRS motor score at baseline instead of initial titration dose. This implies that initial titration dose does not act as an independent risk factor for early onset of LID, but just reflects the severity of motor symptom at initiation of levodopa therapy.

The present data demonstrated that the rate of increase in levodopa dose or LED during treatment is a significant predictor of early onset of LID. Generally, physicians increase the drug dose when the motor symptoms get worse, which means that the rate of dose increase may reflect disease progression. A recent study using serial SPECT imaging data also demonstrated more rapid decrease on putaminal dopamine transporter activity in patients with LID compared with patients without LID \[[@pone.0237472.ref009]\]. Therefore, the present results supports that rapid degeneration of the dopaminergic system is associated with early onset LID.

The levodopa dose and LED at onset of LID of individual patient varied, however the mean dose at onset of LID among patients groups were not different. This suggests that reaching particular level of levodopa dose may be associated with onset of LID. Both higher initial titration dose and rapid dose increase shorten the time to reach a patient-specific drug threshold where the LID develops. However the present results cannot determine which is related with the early onset of LID, the severity of dopaminergic deficit or higher levodopa dose. No clinical trials with a fixed dose of levodopa for several years have been conducted, therefore it is unclear that levodopa dose is the independent risk factor for early onset of LID regardless of severity of dopaminergic denervation. On the other hand, several previous studies have shown that a single administration of overdosed levodopa also induces peak-dose dyskinesia in patients with advanced PD who have never experienced LID before \[[@pone.0237472.ref018], [@pone.0237472.ref019]\], which suggests that long-term exposure to levodopa is not a prerequisite for development of LID in some patients. Therefore, further studies with more evidence are required to clarify whether dopaminergic drug truly induces LID or simply acts as a trigger for onset.

Several limitations of this study need to be addressed. Drawing concrete conclusions from this study is difficult because of its retrospective design without randomized allocation of drug use. Many factors can influence physician choice of drug dose, such as patient age, drug compliance, cognitive status, psychiatric symptoms, and adverse events. Finally, patients who experienced LID within 2 years from levodopa initiation were excluded due to the study design, therefore it is unclear that the study findings are valid in patients with very early LID.

In conclusion, present study demonstrated that rapid dose increase of dopaminergic drug is associated with early onset of LID. However, further studies are required to reveal which is the determinant of onset of LID, severity of the disease or dose of dopaminergic drug.

10.1371/journal.pone.0237472.r001
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RESULTS
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\- The UPDRS is relatively elevated at initiation of Levodopa and/or dopaminergic agonists. It seems that patients were not sufficiently treated. Could you please justify this point?
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\- In the « Risk factor for early LID » section, second line, authors declared that there was a correlation between time to onset of LID and LED but the p value is 0.066 which is above 0.05... (you should also correct the sentence related with this result in the Discussion section)

DISCUSSION

Concerning the sentences from «However the present results... » to « ... acts as a trigger for onset » :

It is well established that the occurrence of LID is secondary both to the dopaminergic denervation AND the levodopa administration. Without one of this factor, LID could not appear. LID occur in patients (or animals) taking Levodopa but only in the presence of dopaminergic degeneration.
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\- Replace « Table 2 » by « Table 1 » in the « Drug » section of the Results.

\- Insert « Table 2 » at the end of the sentence « Multivariable linear regression models ... were associated with early onset of LID ». Same remark for the next sentence.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237472.r002
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Reviewer \#1

\- Could the authors precise how they included the subjects in their study: did they select patients who were known to have early/middle and late LID onset or did they included consecutive patients followed in the different centers and then, classified them in 3 different groups, a posteriori?

Answer) This study was conducted using medical record and study subjects were retrospectively selected according to the study criteria. Now we clarify and rewrite the Method section in revised manuscript.

\- Could the authors argue the reason for which they excluded patients with very early LID? It would have been interesting to include them as they usually reflect severe dopamine depletion.

Answer) Importance of this study is on the method for assessment of drug dose. The rate of dose increase was calculated as (change in dose / treatment duration), therefore relatively short duration of treatment may make the rate of dose increase overestimated. To reduce this chance, we selected patients who encountered LID at least two years after initiation of levodopa. We declare this in Method section.

\- Which criteria did they use to consider that patients were at LID onset? Did they took the medical observation into consideration? The (MDS)-UPDRS part IV for complications of treatment? The Marconi LID scale? Patients questionnaire? We know that slight dyskinesia may occur early in disease evolution but patients are lot always aware of them and are not always able to recognize them as dyskinesia. It may be, thus, a limit to define the precise onset of LID.

Answer) Because this study focused on the time to onset of dyskinesia, presence or absence of LID is the only data needed. Scales for dyskinesia is for assessment of severity of LID were not used in this study. As reviewer comment, many patients are not aware of their dyskinesia. Therefore, we defined the onset of LID based on clinicians' observation. But when patients reported onset of dyskinesia and clinician also observed the dyskinesia, we accepted the day that patients indicated. Now we describe this content in Method section of revised manuscript.

\- In Table 1 the authors reported the number of patients with treatment other than levodopa: was it the treatment, patients had, at time of LID onset?

Answer) Drug other than levodopa was assessed at the time of LID onset. In revised manuscript, we add this information in Table 1 and Result section.

\- In the results section the authors mentioned that female subjects were at higher risk of early LID but they wrote that male subjects were at higher risk in the abstract: please correct.

Answer) We thank for reviewer's correction. We correct the abstract.

\- The authors associated the risk of LID onset with the rapid rate of levodopa /LED increase. However, it is known that LID are also associated with pulsatile post-synaptic dopaminergic stimulation.

\- If data is available, and in order to help interpreting the results of the study, the authors could study and report the way levodopa was prescribed and whether the increase in levodopa dose or LED was associated with an increase in levodopa/LED unitary dose (which may enhance pulsatile answer and promote LID) or whether the increase was associated an increase in the number of daily intakes (a more continuous dopaminergic administration, which may delay the onset of LID). If the authors could add these data, they could develop more precisely the discussion on the pathophysiology of LID and the way to manage PD patients to avoid the occurrence of LID, even in severely depleted patients.

Answer) We selected patients who was treated with levodopa initially, and almost all the patients took levodopa three time a day. And, no patient of this study was treated with continuous intestinal levodopa, subcutaneous apomorphine, rotigotine patch, or deep brain stimulation. Therefore, we think that influence of pulsatile dopaminergic stimulation on onset of LID cannot be explored using this study data and subanalysis suggested by reviewer seems to be impossible in this data

Reviewer \#2

Major comments

MATERIALS AND METHODS

Subjects :

\- Authors chose to perform the analyses with de novo PD patients. It is well known that some PD patients are in fact misdiagnosed (Coarelli et al, J Neurol Sci, 2019 ; Hustad E, Aasly JO. Front Neurol. 2020). How did they ensure that these patients were truly PD patients and not parkinsonian patients from other degenerative disorders such as PSP, MSA,... Which clinical criteria did they use? Did they check these criteria at the beginning of the « PD » disease but also during the follow-up of these patients? It seems strange that authors did not observe other parkinsonian disorders due to initial misdiagnosis, even if they are experts in movement disorders.

Answer) We did not enroll study patients consecutively, but reviewed medical record and selected proper patients for study. During patient selection, other parkinsonian patients such as atypical parkinsonism, dementia with Lewy bodies, frontotemporal dementia, or unspecified disorders were excluded. Now we describe the process of patient selection in detail in Method section of revised manuscript.

\- Did the authors use a score of dyskinesia such as the UDysRS?

Answer) This study focused on the time to onset of dyskinesia, so scales for assessment of severity of LID were not used.

\- In the sentence « Data of patients with... drug dose », the « for » seems not appropriate or something is missing.

Answer) According to reviewer's comment, we revise the sentence.

\- How was performed the motor UPDRS by authors? Was it applied in the OFF state or in the ON state (or intermediate state)? How long after the last medication did the UPDRS have been carried out? Please detail the assessment of the UPDRS score.

Answer) UPDRS score rated at de novo status (just before initiation of levodopa) was used in this study. Now we add this content in Method section of revised manuscript.

RESULTS

\- Demographic characteristics : it is probably more accurate to rename this part « Demographic and clinical characteristics »

Answer) According to reviewer's suggestion, we now rename the title of the paragraph and table 1.

\- The UPDRS motor score was available for only 89 out of 150 patients. Could you precise how many UPDRS motor scores were available in each group (E, M, L). Moreover, in which condition (On? OFF? intermediate?) were assessed these scores?

Answer) As per reviewer's suggest, we now present the number of patients of each group who had been assessed with UPDRS motor score and modified Hoehn and Yahr stage (footnote of Table 1). The used score rated at only drug-naïve status.

\- The UPDRS is relatively elevated at initiation of Levodopa and/or dopaminergic agonists. It seems that patients were not sufficiently treated. Could you please justify this point?

Answer) First, the UPDRS score was rated at de novo status but not in treatment period. The mean UPDRS motor score at de novo status ranges 20 to 25 in most studies. Moreover, we selected patients who initiated medical treatment with levodopa, so patients with mild symptom who was suitable for dopamine agonist or MAO-B inhibitor monotherapy may be excluded from this study.

\- Entacapone increases the occurrence of dyskinesia (Ahn et al., J Clin Neurol. 2007 ; Trenkwalder et al., Neurology. 2019). Did authors observe any difference in dyskinesia occurrence between patients who took entacapone and those who did not take it? Did they look for a difference in each group (E, M, L)?

Answer) The numbers of patients treated with entacapone are already presented in Table 1. There was no difference in number of patients treated with entacapone among E, M, and L groups.

\- In the « Risk factor for early LID » section, second line, authors declared that there was a correlation between time to onset of LID and LED but the p value is 0.066 which is above 0.05... (you should also correct the sentence related with this result in the Discussion section)

Answer) As per reviewer's comment, we revised the sentence for the data.

DISCUSSION

Concerning the sentences from «However the present results... » to « ... acts as a trigger for onset » :

It is well established that the occurrence of LID is secondary both to the dopaminergic denervation AND the levodopa administration. Without one of this factor, LID could not appear. LID occur in patients (or animals) taking Levodopa but only in the presence of dopaminergic degeneration.

Answer) In the paragraph, we focused on the role of levodopa dose. In the clinical setting, levodopa dose was affected by severity of dopaminergic denervation, therefore it is unclear whether levodopa dose is an independent factor for LID or higher levodopa dose is just a consequence of severe dopamine depletion. We discussed this point in this paragraph. Now we revise the paragraph to make it less confusing.

Additionally, as reviewer commented, both dopaminergic denervation and administration of dopaminergic drug are essential for onset of LID. But, Tagasaki et al. (Neuropharmacology 2005) showed that therapeutic dose of levodopa induced LID in DAT blocker-treated squirrel monkey without dopaminergic denervation, and Pearce et al. (Psycholpharmacology 2001) demonstrated that higher dose of levodopa induced LID in dose dependent manner in normal macaque monkey. Therefore, we think that the role of levodopa on LID should be reconsidered.

Minor comments

\- Replace « Table 2 » by « Table 1 » in the « Drug » section of the Results.

\- Insert « Table 2 » at the end of the sentence « Multivariable linear regression models ... were associated with early onset of LID ». Same remark for the next sentence.

Answer) We appreciate reviewer's correction. Now we edit that according to the comment.
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Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson\'s disease

PLOS ONE

Dear Dr. Seo Hyun Kim,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please, answer to the remaining minor comments adressed by the referees.

Please submit your revised manuscript by one month. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Véronique Sgambato

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson\'s disease

PONE-D-20-13495 R1

Research article for the journal Plos One

The authors have revised the manuscript of a retrospective multicenter study on the occurrence of levodopa induced dyskinesia (LID) in Parkinson Disease (PD) patients.

They answered to all comments of the reviewers and corrected the errors in the previous version of the manuscript.

They added data if available.

They have developed more precisely the discussion section.

The manuscript is now clearer than the first version.

The authors did not add any comment on pharmacokinetics and the role of pulsatile administration of levodopa in sensitization and in the development of motor complications (see Nutt J, 1995, Clin Exp Pharmacol Physiol, Nutt J, 2007, Movement Disorders Journal, Sharma et al, 2015 Biomed Pharmacother for example). Most of the patients were taking treatment 3 times a day, as noted by the authors in the answers to comments. It did not seem to be different across groups. This would argue against the idea that high unitary doses of levodopa increase the risk of LID, whereas the rate of increase seem to be more important.

They could perhaps add this comment in the limits of the study section.

They could also add their answer on reviewer 2 comment on the discussion section.

Even though the authors could not confirm that the risk to develop LID is associated with the rate of levodopa increase rather than the initial dose or the severity of dopamine denervation, these data are interesting as they provide clues for the management of patients when trying to avoid LID.

Reviewer \#2: Authors responded to all the queries.

I just have few minor remarks :

\- Please use « levodopa » or « Levodopa » but authors should homogeneize this in all the manuscript

\- Lines 74-75, replace « Among them, we selected patients who medical treatment initiated with levodopa » by « Among them, we selected patients who initiated medical treatment with levodopa »

\- Lines 82-84 : I think authors should rewrite the sentence « When patient reported symptom suggesting LID or dyskinetic movement was observed in the clinic, clinicians have been recording the information for LID » ; « When patient reported symptom suggesting LID or dyskinetic movement was observed in the clinic, clinicians recorded the information for LID

\- Line 89 : « developed within 2 year ... » ; add a « s » for years : « developed within 2 years ... »

\- Line 94 : please put « de novo » in italic

\- Table 1 : « P-value » should be replaced by « p-value »

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1

The authors did not add any comment on pharmacokinetics and the role of pulsatile administration of levodopa in sensitization and in the development of motor complications (see Nutt J, 1995, Clin Exp Pharmacol Physiol, Nutt J, 2007, Movement Disorders Journal, Sharma et al, 2015 Biomed Pharmacother for example). Most of the patients were taking treatment 3 times a day, as noted by the authors in the answers to comments. It did not seem to be different across groups. This would argue against the idea that high unitary doses of levodopa increase the risk of LID, whereas the rate of increase seem to be more important.

They could perhaps add this comment in the limits of the study section.

Answer) Now, we add the contents about the way levodopa was initiated and increased in Method section (lines 104-106 in revised manuscript). In this study, levodopa was usually prescribed three times a day with equal dose, and we increased the levodopa by 50mg per dose (150mg a day) when dose increased was needed. As we answered in previous response to review, there was no change in the number of daily intakes of levodopa during dose increase and there was no difference in number of daily intakes among patients. Therefore, we think that issue for the continuous dopaminergic stimulation is not applicable to this study.

Reviewer \#2

\- Please use « levodopa » or « Levodopa » but authors should homogeneize this in all the manuscript

Answer) Now we use "levodopa" in this revision.

\- Lines 74-75, replace « Among them, we selected patients who medical treatment initiated with levodopa » by « Among them, we selected patients who initiated medical treatment with levodopa »

\- Lines 82-84 : I think authors should rewrite the sentence « When patient reported symptom suggesting LID or dyskinetic movement was observed in the clinic, clinicians have been recording the information for LID » ; « When patient reported symptom suggesting LID or dyskinetic movement was observed in the clinic, clinicians recorded the information for LID

Answer) We revise the sentences according to the suggestion.

\- Line 89 : « developed within 2 year ... » ; add a « s » for years : « developed within 2 years ... »

\- Line 94 : please put « de novo » in italic

\- Table 1 : « P-value » should be replaced by « p-value »

Answer) We correct the errors.
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Dear Dr. Seo Hyun Kim,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Véronique Sgambato

Academic Editor
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Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson\'s disease

Dear Dr. Kim:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.
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PLOS ONE Editorial Office Staff
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